200 related articles for article (PubMed ID: 36843132)
1. Breakthrough: a first-in-class virtual simulator for dose optimization of ACE inhibitors in translational cardiovascular medicine.
Schneider BK; Ward J; Sotillo S; Garelli-Paar C; Guillot E; Prikazsky M; Mochel JP
Sci Rep; 2023 Feb; 13(1):3300. PubMed ID: 36843132
[TBL] [Abstract][Full Text] [Related]
2. Dose-response of benazepril on biomarkers of the classical and alternative pathways of the renin-angiotensin-aldosterone system in dogs.
Sotillo S; Ward JL; Guillot E; Domenig O; Yuan L; Smith JS; Gabriel V; Iennarella-Servantez CA; Mochel JP
Sci Rep; 2023 Feb; 13(1):2684. PubMed ID: 36792677
[TBL] [Abstract][Full Text] [Related]
3. Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensin-aldosterone system in normal dogs.
Lantis AC; Ames MK; Atkins CE; DeFrancesco TC; Keene BW; Werre SR
J Vet Pharmacol Ther; 2015 Feb; 38(1):65-73. PubMed ID: 25224804
[TBL] [Abstract][Full Text] [Related]
4. Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs.
Mochel JP; Peyrou M; Fink M; Strehlau G; Mohamed R; Giraudel JM; Ploeger B; Danhof M
J Vet Pharmacol Ther; 2013 Apr; 36(2):174-80. PubMed ID: 22568394
[TBL] [Abstract][Full Text] [Related]
5. Chronobiology and Pharmacologic Modulation of the Renin-Angiotensin-Aldosterone System in Dogs: What Have We Learned?
Mochel JP; Danhof M
Rev Physiol Biochem Pharmacol; 2015; 169():43-69. PubMed ID: 26428686
[TBL] [Abstract][Full Text] [Related]
6. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
Werner C; Pöss J; Böhm M
Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
[TBL] [Abstract][Full Text] [Related]
7. Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease.
Ames MK; Atkins CE; Eriksson A; Hess AM
J Vet Cardiol; 2017 Jun; 19(3):218-227. PubMed ID: 28576479
[TBL] [Abstract][Full Text] [Related]
8. The effect of enalapril on furosemide-activated renin-angiotensin-aldosterone system in healthy dogs.
Lantis AC; Ames MK; Werre S; Atkins CE
J Vet Pharmacol Ther; 2015 Oct; 38(5):513-7. PubMed ID: 25771846
[TBL] [Abstract][Full Text] [Related]
9. Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs.
Ames MK; Atkins CE; Lee S; Lantis AC; zumBrunnen JR
Am J Vet Res; 2015 Dec; 76(12):1041-50. PubMed ID: 26618728
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs.
Mochel JP; Fink M; Peyrou M; Soubret A; Giraudel JM; Danhof M
Pharm Res; 2015 Jun; 32(6):1931-46. PubMed ID: 25446774
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of a benazepril and spironolactone combination in dogs with congestive heart failure due to myxomatous mitral valve disease: The BEnazepril Spironolactone STudy (BESST).
Coffman M; Guillot E; Blondel T; Garelli-Paar C; Feng S; Heartsill S; Atkins CE
J Vet Intern Med; 2021 Jul; 35(4):1673-1687. PubMed ID: 34028078
[TBL] [Abstract][Full Text] [Related]
13. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype.
Cicoira M; Zanolla L; Rossi A; Golia G; Franceschini L; Cabrini G; Bonizzato A; Graziani M; Anker SD; Coats AJ; Zardini P
J Am Coll Cardiol; 2001 Jun; 37(7):1808-12. PubMed ID: 11401115
[TBL] [Abstract][Full Text] [Related]
14. Renin-angiotensin aldosterone profile before and after angiotensin-converting enzyme-inhibitor administration in dogs with angiotensin-converting enzyme gene polymorphism.
Adin D; Atkins C; Domenig O; DeFrancesco T; Keene B; Tou S; Stern JA; Meurs KM
J Vet Intern Med; 2020 Mar; 34(2):600-606. PubMed ID: 32112596
[TBL] [Abstract][Full Text] [Related]
15. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
Jorde UP
Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of subacute change in RAAS activity (as indicated by urinary aldosterone:creatinine, after pharmacologic provocation) and the response to ACE inhibition.
Ames MK; Atkins CE; Lantis AC; zum Brunnen J
J Renin Angiotensin Aldosterone Syst; 2016; 17(1):1470320316633897. PubMed ID: 27009288
[TBL] [Abstract][Full Text] [Related]
17. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
Mochel JP; Teng CH; Peyrou M; Giraudel J; Danhof M; Rigel DF
Eur J Pharm Sci; 2019 Feb; 128():103-111. PubMed ID: 30508581
[TBL] [Abstract][Full Text] [Related]
18. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
[TBL] [Abstract][Full Text] [Related]
19. Effect of spironolactone and benazepril on furosemide-induced diuresis and renin-angiotensin-aldosterone system activation in normal dogs.
Adin D; Atkins C; Wallace G; Klein A
J Vet Intern Med; 2021 May; 35(3):1245-1254. PubMed ID: 33713485
[TBL] [Abstract][Full Text] [Related]
20. Retrospective evaluation of a dose-dependent effect of angiotensin-converting enzyme inhibitors on long-term outcome in dogs with cardiac disease.
Ward JL; Chou YY; Yuan L; Dorman KS; Mochel JP
J Vet Intern Med; 2021 Sep; 35(5):2102-2111. PubMed ID: 34387901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
